Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

Y K Loke, R Ho, M Smith, O Wong, M Sandhu, W Sage, S Singh

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)


A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.
Original languageEnglish
Pages (from-to)405-415
Number of pages11
JournalJournal of Clinical Pharmacy and Therapeutics
Issue number5
Publication statusPublished - Oct 2013


  • 5-alpha Reductase Inhibitors
  • Azasteroids
  • Cardiovascular Diseases
  • Double-Blind Method
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Male
  • Prostatic Diseases
  • Randomized Controlled Trials as Topic
  • Risk

Cite this